E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.
Jad Chahoud,Dawen Sui,William D. Erwin,Alison M. Gulbis,Martin Korbling,Mingzhi Zhang,Sairah Ahmed,Gheath Alatrash,Paolo Anderlini,Stefan O. Ciurea,Betul Oran,Luis Fayad,Roland L. Bassett,Elias Jabbour,L. Jeffrey Medeiros,Homer A. Macapinlac,Ken H. Young,Issa F. Khouri +17 more
TL;DR: Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL.
Journal ArticleDOI
Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL).
Elias Jabbour,Susan O'Brien,Nitin Jain,Deborah A. Thomas,Guillermo Garcia-Manero,Farhad Ravandi,Gautam Borthakur,Sergernne York,Rebecca Garris,Jorge E. Cortes,Hagop M. Kantarjian +10 more
TL;DR: IO is a CD22 monoclonal antibody bound to a toxin, calecheamicin, and has shown single-agent activity in R/R ALL and addition of IO to effective low-intensity chemotherapy might improve outcome.
Journal ArticleDOI
Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents
Lanshan Huang,Guillermo Garcia-Manero,Elias Jabbour,Maitrayee Goswami,Mark J. Routbort,L. Jeffrey Medeiros,Jeffrey L. Jorgensen,Sa A. Wang +7 more
TL;DR: The findings show the difficulty in eradicating neoplastic myeloid precursors by HMA therapy, thereby resulting in ultimate treatment failure in most patients.
Journal ArticleDOI
Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.
Elias Jabbour,Hagop M. Kantarjian,Dan Jones,Susan O'Brien,Raja Luthra,Guillermo Garcia-Manero,Francis J. Giles,Mary Beth Rios,Srdan Verstovsek,Jorge E. Cortes +9 more
TL;DR: It is concluded that mutations occur frequently among pts with acquired resistance to imatinib; in few instances they can be identified in pts in CGCR; and 3) P-loop mutations may not be associated with worse outcome compared to other mutations.
Journal ArticleDOI
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.
Preetesh Jain,Hagop M. Kantarjian,Nitin Jain,Nicholas J. Short,Cameron C. Yin,Rashmi Kanagal-Shamanna,Joseph D. Khoury,Marina Konopleva,Koji Sasaki,Tapan M. Kadia,Rebecca Garris,Sherry Pierce,Zeev Estrov,William G. Wierda,Jorge E. Cortes,Susan O'Brien,Farhad Ravandi,Elias Jabbour +17 more